AGRX vs. ATXI, ARAV, VRPX, BPTSY, NBY, PHIO, BPTS, ARDS, GOVX, and CYCC
Should you be buying Agile Therapeutics stock or one of its competitors? The main competitors of Agile Therapeutics include Avenue Therapeutics (ATXI), Aravive (ARAV), Virpax Pharmaceuticals (VRPX), Biophytis (BPTSY), NovaBay Pharmaceuticals (NBY), Phio Pharmaceuticals (PHIO), Biophytis (BPTS), Aridis Pharmaceuticals (ARDS), GeoVax Labs (GOVX), and Cyclacel Pharmaceuticals (CYCC). These companies are all part of the "pharmaceutical preparations" industry.
Avenue Therapeutics (NASDAQ:ATXI) and Agile Therapeutics (NASDAQ:AGRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, community ranking, analyst recommendations and valuation.
17.3% of Avenue Therapeutics shares are owned by institutional investors. Comparatively, 10.9% of Agile Therapeutics shares are owned by institutional investors. 1.8% of Avenue Therapeutics shares are owned by company insiders. Comparatively, 0.5% of Agile Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Avenue Therapeutics had 37 more articles in the media than Agile Therapeutics. MarketBeat recorded 38 mentions for Avenue Therapeutics and 1 mentions for Agile Therapeutics. Avenue Therapeutics' average media sentiment score of 0.00 beat Agile Therapeutics' score of -0.08 indicating that Agile Therapeutics is being referred to more favorably in the news media.
Agile Therapeutics received 277 more outperform votes than Avenue Therapeutics when rated by MarketBeat users. Likewise, 67.62% of users gave Agile Therapeutics an outperform vote while only 60.25% of users gave Avenue Therapeutics an outperform vote.
Avenue Therapeutics has a net margin of 0.00% compared to Avenue Therapeutics' net margin of -73.83%.
Avenue Therapeutics has higher earnings, but lower revenue than Agile Therapeutics. Avenue Therapeutics is trading at a lower price-to-earnings ratio than Agile Therapeutics, indicating that it is currently the more affordable of the two stocks.
Avenue Therapeutics has a beta of -0.09, indicating that its stock price is 109% less volatile than the S&P 500. Comparatively, Agile Therapeutics has a beta of 1.25, indicating that its stock price is 25% more volatile than the S&P 500.
Agile Therapeutics has a consensus price target of $8.50, indicating a potential upside of 2,113.54%. Given Avenue Therapeutics' higher probable upside, analysts clearly believe Agile Therapeutics is more favorable than Avenue Therapeutics.
Summary
Agile Therapeutics beats Avenue Therapeutics on 9 of the 15 factors compared between the two stocks.
Get Agile Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Agile Therapeutics Competitors List
Related Companies and Tools
